Antibodies Market, By Drug Type (Monoclonal antibodies, Polyclonal antibodies, Antibody-drug complexes (ADCs), by Disease Indication (CNS Disorders, Cardiovascular, Cancer, Autoimmune Disorders, COVID-19, Others) By End User (Hospitals, Long-term Care Fac

Antibodies Market, By Drug Type (Monoclonal antibodies, Polyclonal antibodies, Antibody-drug complexes (ADCs), by Disease Indication (CNS Disorders, Cardiovascular, Cancer, Autoimmune Disorders, COVID-19, Others) By End User (Hospitals, Long-term Care Facilities, Research institutes), And by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)- Size, Share, Outlook, and Opportunity Analysis, 2023 - 2030

Antibodies are used in therapeutic applications for the treatment of diseases such as cancer, autoimmune diseases, hematological diseases, infectious diseases, and others. The increasing prevalence of cancer is expected to create lucrative opportunities for the growth of manufacturers in the market. Antibodies products come under biological therapeutic products. Biologic manufacturers require approval (similar to pharma drug approval) from the U.S. Food & Drug Administration prior to bringing the product to the market. However, unlike drugs, biologics require Biologics License Applications (BLA) to be filed with the Center for Biologics Evaluation and Research (CBER). Moreover, various government authorities are focused on controlling/lowering drug prices by adding reforms. For instance, the U.S. government is seeking to lower patients' out-of-pocket spending in Medicare by curbing deals that drug manufacturers make with its distribution channel partners such as pharmacy benefit managers, in February 2019 (these deals are responsible for increasing list price of drugs).

Market Dynamics

Increasing adoption of inorganic growth strategies, such as collaboration and partnership by key players in the market to expand their product portfolio, is expected to drive market growth over the forecast period. For instance, in January 2020, MorphoSys AG, biopharmaceutical company collaborated with Incyte Corporation a multinational pharmaceutical company for the development and commercialization of MorphoSys’ tafasitamab, a humanized Fc-engineered monoclonal antibody against CD19.

Key features of the study:

• This report provides in-depth analysis of the global antibodies market, and provides market size (US$ Million) and Compound Annual Growth Rate (CAGR%) for the forecast period (2023–2030), considering 2022 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global antibodies market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study are Key companies covered as a part of this study include Novartis AG, F. Hoffmann-La Roche Ltd., Johnson & Johnson Services, Inc., Takeda Pharmaceutical Company Limited, Amgen Inc., Biogen Inc., Bristol-Myers Squibb Company, AbbVie Inc., Sanofi, Eli Lilly and Co., Iovance Biotherapeutics, Inc., Ultragenyx Pharmaceutical Inc., and Kyowa Kirin Co., Ltd.
• Insights from this report will allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global antibodies market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global antibodies market

Detailed Segmentation:

• Global Antibodies Market, By Drug Type:
• Monoclonal antibodies
• Polyclonal antibodies
• Antibody-drug complexes (ADCs)
• Global Antibodies Market, By Disease Indication:
• CNS Disorders
• Cardiovascular Diseases
• Cancer
• Autoimmune Disorders
• COVID-19
• Others
• Global Antibodies Market, By End User:
• Hospitals
• Long-term Care Facilities
• Research institutes
• Global Antibodies Market, By Region:
• North America
• By Country:
• U.S.
• Canada
• Latin America
• By Country:
• Brazil
• Mexico
• Argentina
• Rest of Latin America
• Europe
• By Country:
• Germany
• U.K.
• France
• Italy
• Spain
• Russia
• Rest of Europe
• Asia Pacific
• By Country
• China
• India
• Japan
• Australia
• South Korea
• ASEAN
• Rest of Asia Pacific
• Middle East
• By Country:
• GCC
• Israel
• Rest of Middle East
• Africa
• By Country/Region:
• South Africa
• Central Africa
• North Africa
• Company Profiles
• Novartis International AG*
• Company Highlights
• Products Portfolio
• Key Highlights
• Financial Performance
• Strategies
• F. Hoffmann-La Roche Ltd.
• Johnson & Johnson Services, Inc.
• Takeda Pharmaceutical Company Limited
• Amgen Inc.
• Biogen Inc.
• Bristol-Myers Squibb Company
• AbbVie Inc.
• Sanofi S.A.
• Eli Lilly and Co.
• Iovance Biotherapeutics, Inc.
• Ultragenyx Pharmaceutical Inc.
• Kyowa Kirin Co., Ltd.

“*” marked represents similar segmentation in other categories in the respective section.